Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program.

Petrie MC, Borlaug BA, Butler J, Davies MJ, Kitzman DW, Shah SJ, Verma S, Jensen TJ, Einfeldt MN, Liisberg K, Perna E, Sharma K and 6 more

Show all authors

Ezekowitz JA, Fu M, Melenovský V, Ito H, Lelonek M, Kosiborod MN

Journal of the American College of Cardiology13 May 2024Cited by 84 (Europe PMC)

PMID38819334DOI10.1016/j.jacc.2024.04.022PepBankPUB-38819334

Publisher page PubMedAsk about this study

Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with obesity-related HFpEF, semaglutide 2.4 mg reduced NT-proBNP at 52 weeks compared with placebo.
In plain wordsIn people with obesity-related heart failure with preserved ejection fraction, semaglutide lowered the heart strain marker NT-proBNP more than placebo.
Peptide
Semaglutide
Outcome
DecreaseNT-proBNP change at 52 weeks
Study
n = 1,145
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
2.4 mg · 52 weeksAs given in this study (human).
Measurements
Estimated treatment ratio
0.82 ratio
NT-proBNP at 52 weeks
Source sentences
Summary
Semaglutide compared with placebo reduced NT-proBNP at 52 weeks (estimated treatment ratio: 0.82; 95% CI: 0.74-0.91; P = 0.0002).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a prespecified secondary analysis of pooled data from 2 double-blind, placebo-controlled, randomized trials
Report a problemFND-3881933401
02HumanRandomized controlled trialEfficacy outcome
In patients with obesity-related HFpEF, semaglutide improved health status more in those with higher baseline NT-proBNP than in those with lower baseline NT-proBNP.
In plain wordsIn people with obesity-related heart failure, semaglutide improved health status more in those with higher baseline NT-proBNP than in those with lower levels.
Peptide
Semaglutide
Outcome
IncreaseKCCQ Clinical Summary Score improvement by baseline NT-proBNP (interaction)
Study
n = 1,145
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
2.4 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
Improvements in health status were more pronounced in those with higher vs lower baseline NT-proBNP (estimated difference: tertile 1: 4.5 points, 95% CI: 0.8-8.2; tertile 2: 6.2 points, 95% CI: 2.4-10.0; tertile 3: 11.9 points, 95% CI: 8.1-15.7; P interaction = 0.02; baseline NT-proBNP as a continuo…
1 context sentence(design, population, supporting numbers)
Summary · context
This was a prespecified secondary analysis of pooled data from 2 double-blind, placebo-controlled, randomized trials
Report a problemFND-3881933402
03HumanRandomized controlled trialEfficacy outcome
In patients with obesity-related HFpEF, semaglutide reductions in body weight were consistent across baseline NT-proBNP levels.
In plain wordsIn people with obesity-related heart failure, semaglutide weight loss was similar whatever the starting NT-proBNP level.
Peptide
Semaglutide
Outcome
No significant changeBody weight reduction by baseline NT-proBNP
Study
n = 1,145
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Studied dose
2.4 mg · 52 weeksAs given in this study (human).
Source sentences
Summary
Reductions in body weight were consistent across baseline NT-proBNP levels (P interaction = 0.21).
1 context sentence(design, population, supporting numbers)
Summary · context
This was a prespecified secondary analysis of pooled data from 2 double-blind, placebo-controlled, randomized trials
Report a problemFND-3881933406
04HumanRandomized controlled trialEfficacy outcome
In patients with obesity-related HFpEF and the lowest baseline NT-proBNP tertile, semaglutide improved health status versus placebo.
In plain wordsIn people with obesity-related heart failure and the lowest NT-proBNP level, semaglutide improved health status more than placebo.
Peptide
Semaglutide
Outcome
IncreaseKCCQ health status improvement, NT-proBNP tertile 1
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
2.4 mg · 52 weeksAs given in this study (human).
Measurements
Estimated difference
4.5 points
tertile 1
Source sentences
Summary
tertile 1: 4.5 points, 95% CI: 0.8-8.2
1 context sentence(design, population, supporting numbers)
Summary · context
This was a prespecified secondary analysis of pooled data from 2 double-blind, placebo-controlled, randomized trials
Report a problemFND-3881933403
05HumanRandomized controlled trialEfficacy outcome
In patients with obesity-related HFpEF and the middle baseline NT-proBNP tertile, semaglutide improved health status versus placebo.
In plain wordsIn people with obesity-related heart failure and a middle NT-proBNP level, semaglutide improved health status more than placebo.
Peptide
Semaglutide
Outcome
IncreaseKCCQ health status improvement, NT-proBNP tertile 2
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
2.4 mg · 52 weeksAs given in this study (human).
Measurements
Estimated difference
6.2 points
tertile 2
Source sentences
Summary
tertile 2: 6.2 points, 95% CI: 2.4-10.0
1 context sentence(design, population, supporting numbers)
Summary · context
This was a prespecified secondary analysis of pooled data from 2 double-blind, placebo-controlled, randomized trials
Report a problemFND-3881933404
06HumanRandomized controlled trialEfficacy outcome
In patients with obesity-related HFpEF and the highest baseline NT-proBNP tertile, semaglutide improved health status versus placebo.
In plain wordsIn people with obesity-related heart failure and the highest NT-proBNP level, semaglutide improved health status more than placebo.
Peptide
Semaglutide
Outcome
IncreaseKCCQ health status improvement, NT-proBNP tertile 3
Study
n: not reported in source
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
2.4 mg · 52 weeksAs given in this study (human).
Measurements
Estimated difference
11.9 points
tertile 3
Source sentences
Summary
tertile 3: 11.9 points, 95% CI: 8.1-15.7
1 context sentence(design, population, supporting numbers)
Summary · context
This was a prespecified secondary analysis of pooled data from 2 double-blind, placebo-controlled, randomized trials
Report a problemFND-3881933405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 3NCT07738276

Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

Shahid Beheshti University of Medical Sciencesn = 60est. 18 Jul 2026 to est. 22 Dec 2027

Heart Failure and Reduced Ejection Fraction · Obesity & Overweight · Tirzepatide

Trial page ClinicalTrials.govUpdated 3 Aug 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.